SCHEMBL12440601

SCHEMBL12440601

CCN1CCCC1C(=O)N(C)C1CCN(c2nc(Nc3ccc(Cl)cc3F)c3cc(F)ccc3n2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 4/20 0.59
HRH4 Q9H3N8 6/20 0.41
TRPC3 Q13507 3/20 0.39
TRPC6 Q9Y210 3/20 0.39
TRPA1 O75762 1/20 0.39
CACNA1C Q13936 1/20 0.39
SCN5A Q14524 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
TRPV4 Q9HBA0 1/20 0.39
HTR3A P46098 2/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
EGFR P00533 1/20 0.39
FGFR1 P11362 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13311322 0.94 CCR4 (0.59) CCR4HRH4TRPC3TRPC6TRPA1
SCHEMBL16885000 0.94 CCR4 (0.59) CCR4HRH4TRPC3TRPC6TRPA1
SCHEMBL13144692 0.91 CCR4 (0.56) CCR4HRH4TRPC3TRPC6TRPA1
SCHEMBL3095318 0.91 CCR4 (0.73) CCR4EGFRFGFR1FLT1FLT4
Hydrochloric Acid SCHEMBL3073062 0.90 CCR4 (0.72) CCR4EGFRFGFR1FLT1FLT4
SCHEMBL13348079 0.88 CCR4 (0.56) CCR4HRH4TRPC3TRPC6TRPA1
SCHEMBL16768158 0.86 CCR4 (0.64) CCR4HRH4TRPC3TRPC6TRPA1
SCHEMBL13451284 0.83 CCR4 (0.59) CCR4HRH4TRPC3TRPC6TRPA1
SCHEMBL13144690 0.83 CCR4 (0.53) CCR4HRH4HTR3APDE4APDE4B
SCHEMBL15494279 0.83 CCR4 (0.82) CCR4HRH4HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466282-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-18 US disclosed
US-20110178057-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178057-A1 HETEROCYCLIC COMPOUND AND USE THEREOF REN, AGT, ACE CCR4 4194/4885HRH4 614/4885TRPC3 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.